Maternal and neonatal outcomes following natalizumab use during pregnancy in women with multiple sclerosis: A multicenter observational study
Continuing natalizumab treatment until late pregnancy was associated with better postpartum clinical and radiological outcomes. Neonatal anthropometric measures were comparable to reference child growth standards. These findings support that late pregnancy natalizumab continuation may be a viable high efficacy strategy for women with highly active MS.
Authors
- Vasileios Mastorodemos (ORCID: https://orcid.org/0000-0002-7397-2930)
- Vasileios Giannopapas (ORCID: https://orcid.org/0000-0001-6210-2086)
- Dimitrios K. Kitsos (ORCID: https://orcid.org/0000-0003-0722-9329)
- Konstantina Stavrogianni (ORCID: https://orcid.org/0000-0002-1221-4618)
- Athanasios K. Chasiotis (ORCID: https://orcid.org/0000-0001-7496-1195)
- Georgios Tagaris
- John Tzartos
- Alexandra Akrivaki
- Fotios Roussos
- Evangelia-Makrina Dimitriadou
- Georgios Tsivgoulis
- Sotirios Giannopoulos
Institutions
- National and Kapodistrian University of Athens (GR)
- University of West Attica (GR)
- General Hospital of Athens G. Genimatas (GR)
- University Hospital of Heraklion (GR)
- University Hospital of Ioannina (GR)
Publication Details
- Journal
- Journal of Clinical Neuroscience
- Published
- 2026-03-07
- DOI
- https://doi.org/10.1016/j.jocn.2026.111977
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00